Nasdaq

Summit Therapeutics plc : Holding(s) in Company

20-09-2017

TR-1: S
tandard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ⁱⁱ :			Summit Therapeutics PLC Sedol BN40HZ0
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights						X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) ⁱⁱⁱ : Participation in placing						X
3. Details of person subject to the notification obligation ^iv
Name			¹ Lansdowne Partners International Limited ² Lansdowne Partners Limited ³ Lansdowne Partners (UK) LLP
City and country of registered office (if applicable)			London, United Kingdom
4. Full name of shareholder(s) (if different from 3.) ^v
Name			HSBC Client Holdings Nominee (UK) Ltd, HSBC Bank Plc Lansdowne Markets (Registered Shareholders)
City and country of registered office (if applicable)			n/a
5. Date on which the threshold was crossed or reached ^vi :			19/09/2017
6. Date on which issuer notified (DD/MM/YYYY):			20/09/2017
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights of issuer ^vii
Resulting situation on the date on which threshold was crossed or reached	15.75%	11.35%		27.11%	70,316,908
Position of previous notification (if applicable)	17.95%	7.53%		25.48%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached ^viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights ^ix					% of voting rights
		Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)			Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00BN40HZ01				11,077,170					15.75%


SUBTOTAL 8. A		11,077,170					15.75%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument		Expiration date ^x	Exercise/ Conversion Period ^xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights
American Depositary Shares (ADS)		N/A	N/A			7,983,330			11.35%
			SUBTOTAL 8. B 1			7,983,330			11.35%

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument	Expiration date ^x		Exercise/ Conversion Period ^xi		Physical or cash settlement ^xii			Number of voting rights	% of voting rights


					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer ^xiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity ^xiv (please add additional rows as necessary)				X
Name ^xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Lansdowne Partners International Limited			27.11%
Lansdowne Partners Limited
Lansdowne Partners (UK) LLP			27.11%

10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held

11. Additional information ^xvi

Place of completion	London
Date of completion	20 September 2017

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Summit Therapeutics plc via GlobeNewswire

HUG#2135734